PRISMA-E 2012 Checklist

Checklist of Ite	of Items for Reporting Equity-Focused Systematic Reviews			
Section	Item	Standard PRISMA Item	Extension for Equity-Focused Reviews	Pg#
Title				
Title	1	Identify the report as a systematic review, meta-analysis, or both.	dentify equity as a focus of the review, if relevant, using the term equity	
Abstract				
Structured	2	2. Provide a structured summary including, as applicable: background; objectives;	State research question(s) related to health equity.	
summary		data sources; study eligibility criteria, participants, and interventions; study appraisa		
		and synthesis methods; results; limitations; conclusions and implications of key		
		findings; systematic review registration number.		
	2A		Present results of health equity analyses (e.g. subgroup analyses or meta-regression).	
	2B		Describe extent and limits of applicability to disadvantaged populations of interest.	
ntroduction				
Rationale	3	Describe the rationale for the review in the context of what is already known.	Describe assumptions about mechanism(s) by which the intervention is assumed to	
			have an impact on health equity.	
	3A		Provide the logic model/analytical framework, if done, to show the pathways through	
Objectives	4	Provide an explicit statement of questions being addressed with reference to	which the intervention is assumed to affect health equity and how it was developed. Describe how disadvantage was defined if used as criterion in the review (e.g. for	
Objectives	4	participants, interventions, comparisons, outcomes, and study design (PICOS).	selecting studies, conducting analyses or judging applicability).	
	4A	participants, interventions, compansons, outcomes, and study design (Ficos).	State the research questions being addressed with reference to health equity	
Methods	44		place the research questions being addressed with reference to health equity	
Protocol and	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web		
registration	,	address), and, if available, provide registration information including registration		
registration		number.		
Eligibility criteria	6	6. Specify study characteristics (e.g., PICOS, length of follow-up) and report	Describe the rationale for including particular study designs related to equity research	
		characteristics (e.g., years considered, language, publication status) used as criteria	questions.	
		for eligibility, giving rationale.		
	6A		Describe the rationale for including the outcomes - e.g. how these are relevant to	
			reducing inequity.	
Information	7	Describe all information sources (e.g., databases with dates of coverage, contact	Describe information sources (e.g. health, non-health, and grey literature sources) that	
sources		with study authors to identify additional studies) in the search and date last	were searched that are of specific relevance to address the equity questions of the	
		searched.	review.	
Search	8	Present full electronic search strategy for at least one database, including any limits	Describe the broad search strategy and terms used to address equity questions of the	
		used, such that it could be repeated.	review.	
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in		
B. L II I' .	40	systematic review, and, if applicable, included in the meta-analysis).		
Data collection	10	Describe method of data extraction from reports (e.g., piloted forms, independently,		
process		in duplicate) and any processes for obtaining and confirming data from investigators.		
Data items	11		List and define data items related to equity, where such data were sought (e.g. using	
Data Itellis	**	and any assumptions and simplifications made.	PROGRESS-Plus or other criteria, context).	
Risk of bias in	12	Describe methods used for assessing risk of bias of individual studies (including	nooness i ius oi other enteria, context,	
individual studies		specification of whether this was done at the study or outcome level), and how this		
		information is to be used in any data synthesis.		
Summary	13	State the principal summary measures (e.g., risk ratio, difference in means).		
measures		, , , , , , , , , , , , , , , , , , , ,		
Synthesis of	14	Describe the methods of handling data and combining results of studies, if done,	Describe methods of synthesizing findings on health inequities (e.g. presenting both	
results		including measures of consistency (e.g., I ²) for each meta-analysis.	relative and absolute differences between groups).	
Risk of bias	15	15. Specify any assessment of risk of bias that may affect the cumulative evidence		

PRISMA-E 2012 Checklist

across studies		(e.g., publication bias, selective reporting within studies).		
Additional	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses,	Describe methods of additional synthesis approaches related to equity guestions, if	
analyses		meta-regression), if done, indicating which were pre-specified.	done, indicating which were pre-specified	
Results				
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the		
		review, with reasons for exclusions at each stage, ideally with a flow diagram.		
Study	18	For each study, present characteristics for which data were extracted (e.g., study	Present the population characteristics that relate to the equity questions across the	
characteristics		size, PICOS, follow-up period) and provide the citations.	relevant PROGRESS-Plus or other factors of interest.	
Risk of bias	19	Present data on risk of bias of each study and, if available, any outcome level		
within studies		assessment (see item 12).		
Results of	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple		
individual studies		summary data for each intervention group (b) effect estimates and confidence		
		intervals, ideally with a forest plot.		
Synthesis of	21	Present results of each meta-analysis done, including confidence intervals and	Present the results of synthesizing findings on inequities (see 14).	
results		measures of consistency.		
Risk of bias	22	Present results of any assessment of risk of bias across studies (see Item 15).		
across studies				
Additional	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses,	Give the results of <u>additional</u> synthesis approaches related to equity objectives, if	
analysis		meta-regression [see Item 16]).	done, (see 16).	
Discussion				
Summary of	24	Summarize the main findings including the strength of evidence for each main		
evidence		outcome; consider their relevance to key groups (e.g., healthcare providers, users,		
		and policy makers).		
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level		
		(e.g., incomplete retrieval of identified research, reporting bias).		
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and	Present extent and limits of applicability to disadvantaged populations of interest and	
	264	implications for future research.	describe the evidence and logic underlying those judgments.	
	26A		Provide implications for research, practice or policy related to equity where relevant	
			(e.g. types of research needed to address unanswered questions).	
Funding				
Funding	27	Describe sources of funding for the systematic review and other support (e.g.,		
	۷,	supply of data); role of funders for the systematic review.		
		paper, o. data,, . o.c or randers for the systematic review.	1	

From: Source: Welch V, Petticrew M, Tugwell P, Moher D, O'Neill J, Waters E, White H, and the PRISMA-Equity Bellagio Group. (2012) PRISMA-Equity 2012 Extension: Reporting Guidelines for Systematic Reviews with a Focus on Health Equity. PLoS Med 9(10): e1001333. doi:10.1371/journal.pmed.1001333

For more information: $\underline{\text{http://equity.cochrane.org/equity-extension-prisma}}$